Legend Biotech price target lowered to $63 from $64 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm's price target on Legend Biotech to $63 from $64 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June